Interview, Fireside Chat
A Conversation with FDA Commissioner Robert Califf | Future of Health Summit 2024
- The FDA is predicted to face daily crises driven by supply chain shortages, food outbreaks, and farm-related issues in distant locations requiring ongoing intervention.
- H5N1 concerns are expected to persist and intensify due to climate change altering crop conditions and expanding the range of disease-transmitting pests.
- Public health complacency is a identified risk, stemming from the difficulty in recognizing major triumphs when nothing happens.
- A widening gap in life expectancy between rural and urban areas, alongside a growing net wealth split, is anticipated to worsen.
- Most Americans are expected to continue lacking access to necessary health care, with the barrier characterized as an issue of delivery rather than innovation.
- The current Congress-defined food budget allocation is predicted to remain skewed toward prioritizing inspections over nutrition.
- The FDA will continue to rely on a self-governance system for regulated entities between inspection cycles, mirroring current food safety farm protocols.
- The FDA is expected to maintain its status as the international "gold standard" for scientific knowledge and decision-making.
- Regulatory bodies anticipate the FDA and CMS collaborating to establish standards for post-market evidence generation.
- New FDA materials will be published to clarify distinctions between the rigorous requirements of early-phase trials and the capabilities of later-phase pragmatic trials.
- Diversity action plans for clinical trials are expected to enter a phase of analysis, creating iterative loops to improve development programs.
- Rural clinical trials will increasingly test digital human interface approaches necessitated by a lack of providers.
- Replacing humans with digital tools is viewed as ineffective; the future of care is predicted to require digital support for human interactions.
- AI models used in situ are expected to evolve and "gobble up" more information, resulting in performance changes that could be either positive or negative.
- Industry adoption of AI will increasingly focus on administrative tasks such as doctor notes, claims, and data, rather than direct patient care.
- Late-phase clinical trials will see increased utilization of pragmatic trial methodologies to achieve larger populations at lower costs.
- The value of accelerated drug approvals regarding "real human benefits" is expected to remain largely unknown to stakeholders at the time of approval.
- The FDA will need to address the challenge of representing 250 ethnicities primarily through post-market pragmatic trials.